Join Growin Stock Community!

Precigen, inc.PGEN.US Overview

US StockHealthcare
(No presentation for PGEN)
My Watchlist

Ticker

Value

empty

There is no following symbol in this watchlist.

PGEN AI Insights

PGEN Overall Performance

PGEN AI Analysis & Strategy

AI Strategy

Browsing restrictions can be lifted for a fee.

PGEN Recent Performance

-1.98%

Precigen, inc.

0.05%

Avg of Sector

-0.31%

S&P500

PGEN PowerScanner

Introduction >>

Power Squeeze

Surfing Trend

1 Day

1 Week

1 Month

PGEN Key Information

PGEN Financial Forecast

chart

Browsing restrictions can be lifted for a fee.

QuarterlyEPS ForecastQoQMaxMin
2026Q1
2026Q2
2026Q3
2026Q4
2027Q1

PGEN Profile

Precigen, Inc. discovers and develops the next generation of gene and cellular therapies in the United States. It also provides disease-modifying therapeutics; genetically engineered swine for regenerative medicine applications; and reproductive and embryo transfer technologies. In addition, the company offers UltraVector platform that incorporates advanced DNA construction technologies and computational models to design and assemble genetic components into complex gene expression programs; mbIL15, a gene that enhances functional characteristics of immune cells; Sleeping Beauty, a non-viral transposon/transposase system; AttSite recombinases, which breaks and rejoins DNA at specific sequences; AdenoVerse technology platform, a library of engineered adenovector serotypes; and L. lactis is a food-grade bacterium. Additionally, it provides RheoSwitch, an inducible gene switch system that provides quantitative dose-proportionate regulation of the amount and timing of target protein expression; kill switches to selectively eliminate cell therapies in vivo; tissue-specific promoters; UltraCAR-T platform for the treatment of cancer; AdenoVerse Immunotherapy, a library of proprietary adenovectors for the gene delivery; and ActoBiotics platform, genetically modified bacteria that deliver proteins and peptides at mucosal sites. Precigen, Inc. has collaboration and license agreements with Alaunos Therapeutics, Inc.; Ares Trading S.A.; Oragenics, Inc.; Castle Creek Biosciences, Inc.; Intrexon Energy Partners, LLC; and Intrexon Energy Partners II, LLC. The company was formerly known as Intrexon Corporation and changed its name to Precigen, Inc. in January 2020. Precigen, Inc. was founded in 1998 and is based in Germantown, Maryland.

Price of PGEN

PGEN FAQ

This disclaimer is provided by TradingValley Inc. and includes any messages, news, research, analysis, prices or other information provided by the Company's website, the application "Growin App" and other services provided through the Company's website. It is only general market information for educational and investment decision-making reference, and does not constitute any investment advice. View Growin Disclaimer

PGEN Earnings Table

Unit : USD

QTRNon-GAAP EPSEPS YoYEPS Surprise %SalesSales YoYSales Surprise %NPM
Current
2025Q4
2025Q3
2025Q2
2025Q1
METRIC
VALUE
vs. INDUSTRY
EPS (TTM)
-0.82
PE Ratio (TTM)
-
Forward PE
-
PS Ratio (TTM)
212.55
PB Ratio
32.20
Price-to-FCF
-
METRIC
VALUE
vs. INDUSTRY
Gross Margin
30.32%
Net Margin
-3912.92%
Revenue Growth (YoY)
59.20%
Profit Growth (YoY)
488.03%
3-Year Revenue Growth
-44.09%
3-Year Profit Growth
-%
METRIC
VALUE
vs. INDUSTRY
EPS (TTM)
-0.82
PE Ratio (TTM)
-
Forward PE
-
PS Ratio (TTM)
212.55
PB Ratio
32.20
Price-to-FCF
-
Gross Margin
30.32%
Net Margin
-3912.92%
Revenue Growth (YoY)
59.20%
Profit Growth (YoY)
488.03%
3-Year Revenue Growth
-44.09%
3-Year Profit Growth
-%

  • When is PGEN's latest earnings report released?

    The most recent financial report for Precigen, inc. (PGEN) covers the period of 2025Q3 and was published on 2025/09/30. This report is prepared according to IFRS/US GAAP standards and includes key financial indicators—Revenue, Profitability, Cash Flow, and Capital Structure. This information is essential for investors evaluating PGEN's short-term business performance and financial health. For the latest updates on PGEN's earnings releases, visit this page regularly.

  • What is the operating profit of PGEN?

    According to the latest financial report, Precigen, inc. (PGEN) reported an Operating Profit of -34.48M with an Operating Margin of -1,180.05% this period, representing a decline of 62.17% compared to the same period last year. Operating Profit reflects the company's core business efficiency and cost control, making it a key indicator for evaluating operational strength and profitability.

  • How is PGEN's revenue growth?

    In the latest financial report, Precigen, inc. (PGEN) announced revenue of 2.92M, with a Year-Over-Year growth rate of 206.61%. Revenue growth can be driven by product mix changes, market share expansion, price adjustments, or international market penetration. Investors should also monitor gross margin and regional revenue distribution for a comprehensive view of growth quality and sustainability.

  • How much debt does PGEN have?

    As of the end of the reporting period, Precigen, inc. (PGEN) had total debt of 98.19M, with a debt ratio of 0.57. Long-term debt comprises a higher/lower proportion. The level of financial leverage directly impacts the company's capital structure and interest coverage. If debt is high, pay attention to interest expenses and refinancing risks. Conversely, a low-leverage structure indicates greater risk tolerance but potentially less growth flexibility.

  • How much cash does PGEN have?

    At the end of the period, Precigen, inc. (PGEN) held Total Cash and Cash Equivalents of 14.32M, accounting for 0.08 of total assets. Both current and quick ratios indicate robust short-term debt repayment ability. High cash reserves typically mean the company has strong liquidity, supporting operational needs, expansion investments, or shareholder returns.

  • Does PGEN go with three margins increasing?

    In the latest report, Precigen, inc. (PGEN) did not achieve the “three margins increasing” benchmark, with a gross margin of 64.6%%, operating margin of -1,180.05%%, and net margin of -11,134.3%%. This demonstrates limited improvement in profitability, which is a key signal for fundamental analysis. Investors should consider margin trends alongside other financial indicators to assess PGEN's profit trajectory and future growth potential.

  • Is PGEN's EPS continuing to grow?

    According to the past four quarterly reports, Precigen, inc. (PGEN)'s earnings per share (EPS) shows a declining trend, with the latest EPS at -1.06. If EPS continues to rise due to revenue growth and cost optimization, it can support P/E valuation recovery and attract long-term investors.

  • What is the FCF of PGEN?

    Precigen, inc. (PGEN)'s Free Cash Flow (FCF) for the period is -29.46M, calculated as Operating Cash Flow minus Capital Expenditures, representing a fall of 25.04% compared with the previous period. Positive FCF growth provides stable funding for dividends, debt repayment, or strategic acquisitions, and is an important measure of true profitability and shareholder return potential.